CORPORATE OVERVIEW May, 2025 ® Forward-looking statements This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, , including statements regarding the estimated market for our product ...

Financial Performance - The company reported a net loss of $69.3 million for the three months ended March 31, 2025, with an accumulated deficit of $906.0 million[101]. - Net loss for the three months ended March 31, 2025, was $69.3 million, compared to a net loss of $39.6 million for the same period in 2024[120]. - Net cash used in operating activities for the three months ended March 31, 2025, was $53.0 million, compared to $20.9 million for the same period in 2024[135]. - Total operating expenses for the three months ended March 31, 2025, were $74.7 million, up from $42.3 million in 2024[120]. - Collaboration revenue decreased by $0.4 million to $0 for the three months ended March 31, 2025, due to the completion of research service obligations under the Collaboration Agreement with UCB[121]. Research and Development - Research and development expenses for the three months ended March 31, 2025, totaled $60.8 million, a significant increase from $27.0 million in the same period of 2024[112]. - The Cerebrum™ platform incurred $42.8 million in research and development expenses for the first quarter of 2025, compared to $12.9 million in the prior year[112]. - Research and development expenses increased by $33.8 million to $60.8 million for the three months ended March 31, 2025, primarily driven by increased spending on the Cerebrum™ platform[122]. - The company plans to initiate the Phase 3 registrational study for elsunersen (formerly PRAX-222) in mid-2025, with topline results expected in the first half of 2026[99]. - The EMPOWER study for vormatrigine in epilepsy patients was initiated in Q3 2024, with topline results expected by mid-2025[97]. - The company anticipates nominating a development candidate for PRAX-100 by mid-2025, with additional candidates expected by the end of 2025[99]. - The company relies on external consultants and organizations for its research and development activities, operating in a "virtual" model since inception[100]. - The Independent Data Monitoring Committee recommended stopping the ulixacaltamide study for futility, but the company will continue both studies to completion[97]. Financial Position and Resources - The company has cash, cash equivalents, and marketable securities of $472.0 million as of March 31, 2025, expected to fund operations into 2028[106]. - Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $472.0 million[126]. - The company expects substantial increases in expenses related to ongoing research and development activities, particularly for clinical trials[139]. - The company anticipates that its cash resources will be sufficient to fund operations into 2028, based on current estimates[140]. - The company currently lacks committed external sources of funds, which may impact its ability to access capital during market volatility[145]. - If additional funds are raised through collaborations or licensing, the company may have to relinquish valuable rights to its technologies or future revenue streams[146]. - The company raised $1.2 billion in aggregate cash proceeds from various transactions since inception through March 31, 2025[126]. Accounting and Risk - The management's financial analysis is based on condensed consolidated financial statements prepared under U.S. GAAP, requiring estimates and assumptions that may differ from actual results[147]. - There have been no changes to critical accounting policies from those described in the Annual Report on Form 10-K filed on February 28, 2025, except as disclosed in the quarterly report[148]. - Recently issued accounting standards are not expected to have a material impact on the company's financial statements or operations[149]. - The company is exposed to market risk related to interest rate changes, but an immediate change of 100 basis points would not materially impact its financial position[150].

Financial Performance - Praxis reported a net loss of $69.3 million for Q1 2025, compared to a net loss of $39.6 million in Q1 2024[12]. - Net loss for Q1 2025 was $69,296,000, compared to a net loss of $39,553,000 in Q1 2024, representing an increase in loss of approximately 75.3%[26]. - Net loss per share attributable to common stockholders increased from $2.84 in Q1 2024 to $3.29 in Q1 2025, a rise of about 15.8%[26]. - Accumulated deficit grew from $836,740,000 on December 31, 2024, to $906,036,000 on March 31, 2025, an increase of about 8.3%[24]. Research and Development - Research and development expenses increased to $60.8 million for Q1 2025, up from $27.0 million in Q1 2024, primarily due to increased expenses related to the Cerebrum™ platform[10]. - Research and development expenses increased to $60,806,000 in Q1 2025, up from $26,984,000 in Q1 2024, reflecting a rise of approximately 125.5%[26]. - Total operating expenses rose to $74,728,000 in Q1 2025, compared to $42,317,000 in Q1 2024, an increase of about 76.4%[26]. - Praxis plans to initiate pivotal studies for relutrigine and elsunersen by mid-2025, targeting developmental and epileptic encephalopathy[1]. Cash and Investments - Praxis reported cash and investments of $472 million as of March 31, 2025, maintaining a runway into 2028[1]. - Cash and cash equivalents decreased by $49,805,000, from $215,372,000 to $165,567,000, representing a decrease of about 23.1%[24]. - Total assets decreased from $483,110,000 on December 31, 2024, to $478,736,000 on March 31, 2025, a decline of approximately 0.8%[24]. Collaboration Revenue - Praxis did not recognize any collaboration revenue in Q1 2025, a decrease from $0.4 million in Q1 2024, due to the completion of obligations under an agreement with UCB[9]. - Collaboration revenue dropped to $0 in Q1 2025, down from $431,000 in Q1 2024, indicating a significant decline[26]. Clinical Studies and Results - The registrational cohort of the EMBOLD study is on track for topline results no later than the first half of 2026[2]. - Topline results for vormatrigine from the RADIANT study are expected by mid-2025, with additional results from the POWER1 study anticipated in the second half of 2025[2]. - The EMPOWER registrational study has over 3,000 patients registered to date, supporting recruitment for the RADIANT and POWER1 studies[5]. - The Phase 1 food effect study for vormatrigine demonstrated that food intake does not significantly impact its absorption, enhancing dosing flexibility[3]. - The Essential3 study for ulixacaltamide is expected to complete topline readout in Q3 2025, despite an interim analysis recommending study stoppage for futility[5]. Other Income - Other income increased from $2,333,000 in Q1 2024 to $5,432,000 in Q1 2025, reflecting an increase of approximately 133.5%[26].

On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfol ...

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT. The webinar, hosted by the Praxis management team, will focus on the company’s clinical p ...

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April: Praxis management will be presenting a corporate overview at the 24th Annual Needham Virtual Healthcare Conference, ta ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in five upcoming investor conferences: Praxis management will be presenting a corporate overview at the 45th Annual TD Cowen Health Care Conference, taking place at t ...

Core Insights - The article emphasizes the author's expertise in healthcare and technology investments, particularly in biotech stocks, by analyzing clinical data and market dynamics [1] - The author utilizes financial theory and DCF modeling to identify key valuation drivers and make scenario-based forecasts [1] Group 1: Author's Background - The author has been writing for Seeking Alpha since 2017, focusing on healthcare and technology investments [1] - The author has a background as a Registered Nurse, which aids in the analysis of biotech stocks [1] - An MBA provides the author with a foundation in financial theory, allowing for a broader investment analysis [1] Group 2: Analytical Approach - The author evaluates clinical data, treatment guidelines, and market dynamics to analyze biotech stocks [1] - Key valuation drivers are identified through DCF modeling for scenario-based forecasts [1] - The author's thinking is influenced by literature such as "Superforecasting" and "Fooled by Randomness" [1]

Group 1 - Praxis Precision Medicines reported a quarterly loss of $2.94 per share, slightly better than the Zacks Consensus Estimate of a loss of $2.96, and an improvement from a loss of $2.97 per share a year ago, indicating an earnings surprise of 0.68% [1] - The company achieved revenues of $7.46 million for the quarter ended December 2024, significantly surpassing the Zacks Consensus Estimate by 1,467.86%, compared to revenues of $0.52 million in the same quarter last year [2] - The stock has underperformed, losing about 15.5% since the beginning of the year, while the S&P 500 has declined by only 0.3% [3] Group 2 - The earnings outlook for Praxis Precision Medicines is mixed, with the current consensus EPS estimate for the coming quarter at -$2.80 on $0.5 million in revenues, and -$12.22 on $1.91 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8] - Atara Biotherapeutics, a peer in the same industry, is expected to report a quarterly loss of $3.82 per share, reflecting a year-over-year change of +72.7%, with revenues projected to be $13.1 million, up 208.2% from the previous year [9]

Financial Performance - The company reported net losses of $182.8 million and $123.3 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $836.7 million as of December 31, 2024[487]. - The net loss for 2024 was $182.819 million, compared to a net loss of $123.277 million in 2023, indicating a year-over-year increase in losses of approximately 48%[577]. - The net loss for the quarter ending September 30, 2024, was $58,679, compared to a net loss of $51,910 for the quarter ending June 30, 2024, indicating a sequential increase in losses of about 13.5%[584]. - The company reported a net loss of $32,677 for the quarter ending June 30, 2024, which was an improvement compared to a net loss of $39,553 for the quarter ending March 31, 2024[584]. - The balance of accumulated deficit increased to $(836,740) as of December 31, 2024, from $(778,061) at September 30, 2024, reflecting a worsening of approximately 7.5%[584]. Revenue Generation - The company has not generated any revenue from product sales since inception and does not expect to do so for several years, but recognized $8.6 million and $2.4 million of collaboration revenue from a partnership with UCB Biopharma SRL during the years ended December 31, 2024 and 2023, respectively[502]. - Collaboration revenue rose by $6.1 million to $8.6 million in 2024, primarily due to an option exercise fee from UCB[519]. - The Company recognized $8.6 million in collaboration revenue for the year ended December 31, 2024, compared to $2.4 million for the year ended December 31, 2023[680]. - Upon UCB exercising its option in December 2024, the Company recognized a $6.0 million option exercise fee as collaboration revenue[679]. Cash and Funding - The company has cash, cash equivalents, and marketable securities of $469.5 million as of December 31, 2024, which are expected to fund operations into 2028[498]. - The company raised $1.1 billion in aggregate cash proceeds from various stock offerings since inception[523]. - A public offering in April 2024 generated approximately $216.0 million in net proceeds from the sale of common stock[495]. - The company completed a public offering in January 2024, generating approximately $161.6 million in net proceeds after expenses[527]. - The company expects its cash and marketable securities will be sufficient to fund operations for at least one year from the issuance of the financial statements[598]. Research and Development - Total research and development expenses increased by $65.6 million to $152.4 million in 2024, up from $86.8 million in 2023[507]. - The company plans to continue advancing its product candidates and expanding its research and development activities, requiring substantial additional funding[488]. - The company anticipates that research and development expenses will be maintained or increase as product candidates advance through development[507]. - The company is focused on developing therapies for central nervous system disorders through its two proprietary platforms, Cerebrum™ and Solidus™, with multiple clinical-stage product candidates[592]. Stock and Equity - A reverse stock split of 1-for-15 was executed on November 28, 2023, affecting the company's common stock[499]. - The company's additional paid-in capital rose to $1.282 billion in 2024, up from $723.577 million in 2023, reflecting an increase of about 77%[575]. - The weighted average common shares outstanding increased to 17,906,794 in 2024 from 6,594,316 in 2023, indicating a growth of approximately 172%[577]. - The total number of shares outstanding increased from 17,755,506 on June 30, 2024, to 19,422,358 by December 31, 2024, representing an increase of approximately 9.4%[584]. Operating Expenses - Total operating expenses rose to $208.718 million in 2024, compared to $128.820 million in 2023, reflecting an increase of about 62%[577]. - General and administrative expenses increased by $14.3 million to $56.3 million in 2024, up from $42.1 million in 2023[518]. - The Cerebrum™ platform saw a $61.9 million increase in expenses, mainly driven by a $49.8 million rise in spending for the ulixacaltamide program[520]. - The company incurred stock-based compensation expenses of $41.4 million in 2024, up from $24.9 million in 2023, reflecting a 66% increase[590]. Clinical Trials and Studies - The Phase 3 Essential3 clinical trials for ulixacaltamide are ongoing, with topline results expected in the third quarter of 2025[483]. - The company announced positive results from the Photo-Paroxysmal Response study for vormatrigine in Q1 2024 and has initiated multiple studies to gather further data[484]. - The EMBOLD study for relutrigine has shown positive topline results from the first cohort, with the second cohort currently enrolling and results expected in the first half of 2026[484]. Tax and Deferred Assets - The company has U.S. federal and state net operating loss carryforwards that may offset future taxable income, beginning to expire in 2035[516]. - The company has not recorded any U.S. federal or state income tax benefits for net losses incurred since inception[516]. - The Company assesses the likelihood of recovering deferred tax assets based on future taxable income and establishes a valuation allowance if necessary[647]. Collaboration Agreements - As of December 31, 2024, the Company had an option and license agreement with UCB Biopharma SRL, entered into in December 2022, and a collaboration and license agreement with Tenacia Biotechnology, entered into in January 2024[635]. - The Company entered into a Collaboration Agreement with UCB in December 2022, receiving a $5.0 million upfront payment for research services[677]. - The Collaboration Agreement allows UCB to in-license global development and commercialization rights, with potential milestone payments totaling up to $98.5 million and tiered royalties on net sales[677].